The Generation of iPSCs Expressing Interferon-Beta Under Doxycycline-Inducible Control

Area of Science:

• Stem Cell Biology
• Immunology
• Gene Editing

Background:

• Type 1 interferons (IFN-Is) possess significant antiviral, antitumor, and immunoregulatory functions, indicating therapeutic potential.
• Systemic administration of IFN-Is can lead to side effects, and their effects in specific pathological conditions remain inconclusive.
• Local, regulated IFN-I production via cell-based therapies could overcome limitations associated with systemic administration.

Purpose of the Study:

• To generate genetically modified human induced pluripotent stem cells (iPSCs) for controlled local production of interferon beta (IFNB1).
• To establish a cellular model for investigating the biological and therapeutic effects of IFNB1.
• To create a platform for generating diverse cell types with inducible IFNB1 expression.

Main Methods:

• Utilized CRISPR/Cas9 technology to generate doxycycline-inducible IFNB1-overexpressing iPSC lines (IFNB-iPSCs) and control lines (TA-iPSCs).
• Confirmed pluripotency of generated cell lines through morphology, expression of key markers (OCT4, SOX2, TRA 1-60, NANOG), and differentiation potential.
• Validated IFNB1 gene and protein upregulation in IFNB-iPSCs upon doxycycline induction.

Main Results:

• Successfully generated four iPSC lines: three IFNB1-overexpressing (IFNB-iPSCs) and one control (TA-iPSCs).
• Confirmed pluripotency and stable genetic modification in all generated iPSC lines.
• Demonstrated significant, doxycycline-inducible upregulation of IFNB1 RNA (126-816-fold) and protein in IFNB-iPSCs.

Conclusions:

• The generated IFNB-iPSCs provide a robust cellular model for studying interferon beta's effects on cell activity and differentiation.
• This platform facilitates the development of novel cell-based therapies with controlled local IFN-I production.
• The study establishes a valuable tool for in-depth analysis of IFNB1's biological roles and therapeutic applications.